PARP inhibitor re-treatment: the future of maintenance therapy for relapsed ovarian cancer?
A significant progression-free survival improvement after re-treatment with olaparib was reported in the OReO/ENGOT Ov-38 trial
How to bridge the gap between academia and industry
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.
BrighTNess trial: no benefit from the addition of veliparib to neoadjuvant chemotherapy in TNBC
Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival
More than one in six cancer patients experience long-term effects of COVID-19
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery
CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years